| Dr Joseph Chappelle, MD | |
|
4 Technology Dr, East Setauket, NY 11733-4080 | |
| (631) 444-4686 | |
| Not Available |
| Full Name | Dr Joseph Chappelle |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 14 Years |
| Location | 4 Technology Dr, East Setauket, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346412855 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 261384 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Suny/stony Brook University Hospital | Stony brook, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Associates In Obstetrics And Gynecology University Faculty | 9032001045 | 93 |
News Archive
Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.
Footstar, Inc. announced today that certain of its subsidiaries have entered into a definitive merger agreement with CPEX Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, in a transaction valued at approximately $76.6 million, plus fees and expenses relating to the transaction.
House Energy and Commerce Committee Chair John Dingell (D-Mich.) on Thursday at a forum sponsored by the Center for American Progress said increasing the federal tobacco tax might not be a practical way to fund a reauthorization of SCHIP and indicated that a better funding source would be to reduce Medicare Advantage payments, CQ HealthBeat reports.
Arizona's contribution to the accelerated development of new, safe and effective medicines to help treat suffering patients in the US and around the world, will become greater following the signing of new deal between Arizona State University and Quintiles (www.quintiles.com), a global integrated biopharmaceutical services company which is a leader in managing clinical research.
› Verified 6 days ago
| Entity Name | University Associates In Obstetrics & Gynecology University Faculty P |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538114723 PECOS PAC ID: 9032001045 Enrollment ID: O20040325001243 |
News Archive
Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.
Footstar, Inc. announced today that certain of its subsidiaries have entered into a definitive merger agreement with CPEX Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, in a transaction valued at approximately $76.6 million, plus fees and expenses relating to the transaction.
House Energy and Commerce Committee Chair John Dingell (D-Mich.) on Thursday at a forum sponsored by the Center for American Progress said increasing the federal tobacco tax might not be a practical way to fund a reauthorization of SCHIP and indicated that a better funding source would be to reduce Medicare Advantage payments, CQ HealthBeat reports.
Arizona's contribution to the accelerated development of new, safe and effective medicines to help treat suffering patients in the US and around the world, will become greater following the signing of new deal between Arizona State University and Quintiles (www.quintiles.com), a global integrated biopharmaceutical services company which is a leader in managing clinical research.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Chappelle, MD 4 Technology Dr, East Setauket, NY 11733-4080 Ph: (631) 444-4686 | Dr Joseph Chappelle, MD 4 Technology Dr, East Setauket, NY 11733-4080 Ph: (631) 444-4686 |
News Archive
Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.
Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; OTC ADR: MBLTY), today announced that the company's product development strategy has been significantly strengthened by novel composition of matter claims granted by the United States Patent and Trade Mark Office (USPTO) in two distinct patent families to which Mesoblast has exclusive worldwide commercial rights.
Footstar, Inc. announced today that certain of its subsidiaries have entered into a definitive merger agreement with CPEX Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, in a transaction valued at approximately $76.6 million, plus fees and expenses relating to the transaction.
House Energy and Commerce Committee Chair John Dingell (D-Mich.) on Thursday at a forum sponsored by the Center for American Progress said increasing the federal tobacco tax might not be a practical way to fund a reauthorization of SCHIP and indicated that a better funding source would be to reduce Medicare Advantage payments, CQ HealthBeat reports.
Arizona's contribution to the accelerated development of new, safe and effective medicines to help treat suffering patients in the US and around the world, will become greater following the signing of new deal between Arizona State University and Quintiles (www.quintiles.com), a global integrated biopharmaceutical services company which is a leader in managing clinical research.
› Verified 6 days ago
James Bernasko, M.D Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 4 Technology Dr, Stony Brook University Physicians, East Setauket, NY 11733 Phone: 631-444-4686 | |
Dr. Todd R Griffin, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6 Technology Dr, East Setauket, NY 11733 Phone: 631-444-4686 | |
Dr. Melissa Strafford, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4 Technology Dr, East Setauket, NY 11733 Phone: 631-444-4686 | |
Dr. Cecilia Avila, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6 Technology Dr, East Setauket, NY 11733 Phone: 631-444-4686 | |
Philip Schoenfeld, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 100 S Jersey Ave Unit 16, East Setauket, NY 11733 Phone: 631-689-6400 | |
David John Garry, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6 Technology Dr, East Setauket, East Setauket, NY 11733 Phone: 631-444-4686 Fax: 631-444-4622 | |
Dr. Jennifer Marie Blaber, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 140 N Belle Mead Ave, East Setauket, NY 11733 Phone: 631-444-4686 |